The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Viral Arthritis Vaccine Market From 2026 To 2030?

The viral arthritis vaccine market size has seen swift expansion in recent years. It is anticipated to expand from $6.66 billion in 2025 to $7.36 billion in 2026, registering a compound annual growth rate (CAGR) of 10.6%. The historical surge in this market is primarily due to the history of chikungunya outbreaks, progress in vaccine platforms, global immunization initiatives, studies on zoonotic viruses, and efforts in public health preparedness.

The viral arthritis vaccine market is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $11.09 billion by 2030, progressing at a compound annual growth rate (CAGR) of 10.8%. This projected increase during the forecast period is driven by factors such as advanced vaccine platforms, the emergence of arbovirus threats, expedited clinical trials, increased global travel leading to exposure, and the broader implementation of preventive immunization. Key developments expected during this period involve mRNA-based viral arthritis vaccines, recombinant vector vaccine technologies, multivalent vaccines targeting arthritogenic viruses, agile vaccine design strategies, and enhanced adjuvanted immunogenic formulations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33349&type=smp

What Drivers Are Expected To Influence The Viral Arthritis Vaccine Market During The Forecast Period?

The increasing prevalence of mosquito-borne viral infections is anticipated to boost the expansion of the viral arthritis vaccine market moving forward. These infections are diseases transmitted to humans through the bite of infected mosquitoes, including viruses like chikungunya, Zika, and dengue, which can manifest as fever, joint pain, rash, and, in some instances, long-term complications such as viral arthritis. The escalation of mosquito-borne viral infections stems from climate change, leading to warmer climates and altered precipitation patterns that broaden mosquito habitats and breeding seasons. A viral arthritis vaccine aids in curbing mosquito-borne viral infections by preventing infection and disease advancement from viruses that cause joint inflammation, thereby lowering transmission risks and the disease burden in affected populations. For instance, in 2024, as per the World Health Organization (WHO), a Switzerland-based intergovernmental body, over 7.6 million cases were documented globally by April, which is three times the number reported during the same period in 2023, with the transmission ongoing across more than 90 countries. Therefore, the growing occurrence of mosquito-borne viral infections is a significant impetus for the growth of the viral arthritis vaccine market.

Which Segments Are Included In The Analysis Of The Viral Arthritis Vaccine Market?

The viral arthritis vaccine market covered in this report is segmented –

1) By Type: Viral Arthritis Vaccine, Live; Viral Arthritis Vaccine, Inactivated

2) By Virus Targeted: Chikungunya Virus; Rubella Virus; Parvovirus; Other Viral Arthritis-Causing Viruses

3) By Application: Farms; Individual

4) By End-User: Hospitals And Clinics; Vaccination Centers; Homecare; Government Programs

Subsegments:

1) By Viral Arthritis Vaccine, Live: Single Dose; Combination Dose; Recombinant Live Vaccine

2) By Viral Arthritis Vaccine, Inactivated: Whole Virus Inactivated Vaccine; Split Virus Inactivated Vaccine; Adjuvanted Inactivated Vaccine

Which Trends Are Impacting The Growth Of The Viral Arthritis Vaccine Market?

Leading firms within the viral arthritis vaccine market are concentrating on developing novel vaccine candidates, including live-attenuated and next-generation chikungunya vaccines, to meet the increasing demand for effective prophylaxis against viral-induced joint discomfort and chronic arthritic issues, especially among susceptible groups. These live-attenuated and next-generation chikungunya vaccines represent sophisticated formulations intended to prevent chikungunya virus infection by generating robust and enduring immune responses. Specifically, live-attenuated vaccines utilize attenuated viral forms to imitate natural infection closely and offer lasting protection, while next-generation vaccines leverage contemporary platforms like viral vectors, recombinant proteins, or innovative attenuation methods to improve safety, immunogenicity, and wider applicability across populations. As an illustration, in June 2025, Bavarian Nordic A/S, a biotechnology company based in Denmark, commenced a Phase 3 clinical trial for its chikungunya vaccine in children. This initiative seeks to extend protective benefits to pediatric populations in endemic areas, given that exposure in early life can result in a substantial disease burden. This advancement into late-stage clinical evaluation demonstrates increasing confidence in the vaccine’s safety and immune-response profile. It also highlights ongoing endeavors to widen age suitability, bolster community-level immunity, and mitigate the global, long-term consequences of chikungunya-related viral arthritis.

Which Companies Are Leading Innovation In The Viral Arthritis Vaccine Market?

Major companies operating in the viral arthritis vaccine market are Bavarian Nordic A/S, Serum Institute of India Private Limited, Valneva SE, Bharat Biotech International Limited, Panacea Biotec Ltd., The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd.

Read the full viral arthritis vaccine market report here:

https://www.thebusinessresearchcompany.com/report/viral-arthritis-vaccine-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Viral Arthritis Vaccine Market?

North America was the largest region in the viral arthritis vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral arthritis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Viral Arthritis Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33349&type=smp

Browse Through More Reports Similar to the Global Viral Arthritis Vaccine Market 2026, By The Business Research Company

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Vaccine Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

Rotavirus Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/rotavirus-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.